Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Now approved for both acute and chronic HCV in adults and children aged 3 and above
This strategic expansion marks a significant step in the company's global growth strategy
25 women students to receive internship, training, and mentorship in Life Sciences segment
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
_256_384.jpg)
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
Subscribe To Our Newsletter & Stay Updated
